FOLLOWUS
1. The First Affiliated Hospital of Soochow University,Jiangsu Province,Suzhou,China
2. The Hospital of Traditional Chinese Medicine of Jiangsu Province,Nanjing,China
纸质出版日期:2012,
网络出版日期:2011-7-30,
Scan for full text
Wei, Mg., Sun, W., Xiong, Ph. et al. Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤) on adriamycin-induced nephropathy in rats., Chin. J. Integr. Med. 18, 591–598 (2012). https://doi.org/10.1007/s11655-011-0816-x
Ming-gang Wei, Wei Sun, Pei-hua Xiong, et al. Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤) on adriamycin-induced nephropathy in rats[J]. Chinese Journal of Integrative Medicine, 2012,18(8):591-598.
Wei, Mg., Sun, W., Xiong, Ph. et al. Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤) on adriamycin-induced nephropathy in rats., Chin. J. Integr. Med. 18, 591–598 (2012). https://doi.org/10.1007/s11655-011-0816-x DOI:
Ming-gang Wei, Wei Sun, Pei-hua Xiong, et al. Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤) on adriamycin-induced nephropathy in rats[J]. Chinese Journal of Integrative Medicine, 2012,18(8):591-598. DOI: 10.1007/s11655-011-0816-x.
To investigate the antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤
MDBD) on adraimycin-induced nephropathy in rats. Thirty-two male Sprague Dawley albino rats were randomly divided into 4 groups: the control
model
and two treatment groups
with 8 in each group. Nephropathy was induced in the latter 3 groups by intravenous injection of adriamycin. Rats in the two treatment groups received intragastric administration of benazepri (a positive control) or MDBD
which is composed of extracts of Radix Angelicae sinensis
Astragalus membranaceus (Fisch.) Bge and Rhizoma chuanxiong. Serum albumin
blood lipids
24-h urine protein and urine N-acetyl-b-D-glucosaminidase (NAG) were measured every 2 weeks. The ratio of kidney to body weight was measured. The expressions of extracellular matrix proteins in the renal cortex
including colleagen IV (Col-IV) and fibronectin (FN)
were examined by immunohistochemistry
and the transcription of genes encoding transforming growth factor β1 (TGF-β1)
the tissue inhibitors of matrix metalloproteinase 1 (TIMP-1) and matrix metalloproteinase 9 (MMP-9) were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) at the end of the 8-week treatment. Compared with the untreated rats in the model group
MDBD significantly increased serum albumin
lowered the blood lipids and decreased the ratio of kidney to body weight. MDBD significantly reduced the excretion levels of urinary protein and NAG as well as the accumulation of extracellular matrix (ECM)
including Col-IV and FN
in the renal cortex. Further
MDBD decreased TIMP-1 and TGF-β1 gene expressions and increased MMP-9 gene expression in the kidney. MDBD was effective in treating the rat model of nephropathy. The clinical benefit was associated with reduction of renal fibrosis. The antifibrotic effect of MDBD may be mediated through the regulation of TIMP-1
MMP and TGF-β1 gene expressions.
To investigate the antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤
MDBD) on adraimycin-induced nephropathy in rats. Thirty-two male Sprague Dawley albino rats were randomly divided into 4 groups: the control
model
and two treatment groups
with 8 in each group. Nephropathy was induced in the latter 3 groups by intravenous injection of adriamycin. Rats in the two treatment groups received intragastric administration of benazepri (a positive control) or MDBD
which is composed of extracts of Radix Angelicae sinensis
Astragalus membranaceus (Fisch.) Bge and Rhizoma chuanxiong. Serum albumin
blood lipids
24-h urine protein and urine N-acetyl-b-D-glucosaminidase (NAG) were measured every 2 weeks. The ratio of kidney to body weight was measured. The expressions of extracellular matrix proteins in the renal cortex
including colleagen IV (Col-IV) and fibronectin (FN)
were examined by immunohistochemistry
and the transcription of genes encoding transforming growth factor β1 (TGF-β1)
the tissue inhibitors of matrix metalloproteinase 1 (TIMP-1) and matrix metalloproteinase 9 (MMP-9) were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) at the end of the 8-week treatment. Compared with the untreated rats in the model group
MDBD significantly increased serum albumin
lowered the blood lipids and decreased the ratio of kidney to body weight. MDBD significantly reduced the excretion levels of urinary protein and NAG as well as the accumulation of extracellular matrix (ECM)
including Col-IV and FN
in the renal cortex. Further
MDBD decreased TIMP-1 and TGF-β1 gene expressions and increased MMP-9 gene expression in the kidney. MDBD was effective in treating the rat model of nephropathy. The clinical benefit was associated with reduction of renal fibrosis. The antifibrotic effect of MDBD may be mediated through the regulation of TIMP-1
MMP and TGF-β1 gene expressions.
Chinese herbsadriamycin-induced nephropathy ratmechanismantifibrosis effect
Chinese herbsadriamycin-induced nephropathy ratmechanismantifibrosis effect
Gabbiani G. The biology of the myofibroblast. Kidney Int 1992;41:530–532.
Muchaneta-Kubara EC, el Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 1997;12:905–915.
Jerums G, Panagiotopoulos S, Tsalamandris C, Allen TJ, Gilbert RE, Comper WD. Why is proteinuria such an important risk factor for progression in clinical trial? Kidney Int 1997;52:S87–S92.
Rysz J, Pedzik A, Markuszewski L, Kujawski K, Blaszczak R, Olszewski R. The role of metalloproteinases in kidney pathophysiology. Pol Merkur Lekarski (Polish) 2005;19:812–815.
Ahmed AK, Haylor JL, El Nahas AM, Johnson TS. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int 2007;71:755–763.
Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121–131.
Liu S, Li Y, Zhao H, Chen D, Huang Q, Wang S, et al, Huang H. Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats. Mol Cell Biochem 2006;284:9–17.
Wei MG, Xiong PH, Zhang L, Chen AP. The protective effect of Chinese medicine on IgA nephritis-induced renal tubule lesion. J Tradit Chin Med (Chin) 2006;47:839–840.
Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 1982;46:16–23.
Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001;43:211–218.
Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974–2984.
Dance N, Price RG, Cattell WR, Lansdell J, Richards B. The excretion of N-acetyl-beta-glucosaminidase and betagalactosidase by patients with renal disease. Clin Chim Acta 1970;27:87–92.
Oseto S, Moriyama T, Kawada N, Nagatoya K, Takeji M, Ando A, et al. Therapeutic effect of all-transretinoic acid on rats with anti-GBM antibody glomerulonephritis. Kidney Int 2003;64:1241–1252.
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286–1292.
Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597–604.
McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ. The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta 1991;1091:231–235.
Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988;263:7741–7746.
Fu XY, Park WC, Heineche JW. Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 2008;19:2–13.
Steinmann-Niggli K, Ziswiler R, Küng M, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thyl.1 nephritis. J Am Soc Nephrol 1998;9:397–407.
McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH. Characterization of glomerular epithelial cell metalloproteinaseas matrix metalloproteinase-9 with chanced expression in a model of membranous nephropathy. J Clin Invest 1996;97:1094–1101.
Wagner J, Dechow C, Morath C, Lehrke I, Amann K, Waldherr R, et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000;11:1479–1487.
Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J 2006;119:814–821.
0
浏览量
82
Downloads
13
CSCD
关联资源
相关文章
相关作者
相关机构